• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Celgene

Here are the pharma companies accused of blocking generic competition

May 17, 2018 By Sarah Faulkner

Pills

To prove a generic drug is as safe and effective as the branded version, pharmaceutical companies have to hand over upwards of 1,000 doses of the product to a generic developer. But if the manufacturer creating the generic drug cannot get its hands on enough sample, the development and testing process slows down. It could […]

Filed Under: Featured, Food & Drug Administration (FDA), Pharmaceuticals, Wall Street Beat Tagged With: Actelion Pharmaceuticals, Celgene, FDA, Gilead Sciences, GlaxoSmithKline plc, Johnson & Johnson, Novartis, Valeant Pharmaceuticals

Verily, Sanofi and other industry players team up with NIH to advance Parkinson’s therapies

January 30, 2018 By Sarah Faulkner

National Institutes of Health logo

The National Institutes of Health is joining forces with the tech and pharmaceutical industries to speed the development of new drugs for Parkinson’s disease and identify biomarkers for the debilitating condition. Companies participating in the public-private partnership include Celgene (NSDQ:CELG), GlaxoSmithKline (NYSE:GSK), The Michael J. Fox Foundation for Parkinson’s Research, Pfizer (NYSE:PFE), Sanofi (NYSE:SNY) and Verily. Combined the […]

Filed Under: Clinical Trials, Featured, Neurological, Pharmaceuticals, Wall Street Beat Tagged With: Celgene, GlaxoSmithKline plc, michaeljfoxfoundation, National Institutes of Health, Pfizer Inc., Sanofi-Aventis, Verily

Novocure misses sales, earnings estimates in Q2

July 27, 2017 By Sarah Faulkner

Novocure

Shares in Novocure (NSDQ:NVCR) fell today after the oncology company missed expectations on Wall Street with its second quarter results. The St. Helier, N.J.-based company reeled in its losses to -$21.2 million on sales of $38.4 million for the 3 months ended June 30, for bottom-line growth of 48% on sales growth of 114% compared with […]

Filed Under: Drug-Device Combinations, Featured, MassDevice Earnings Roundup, Oncology, Wall Street Beat Tagged With: Celgene, NovoCure

Novocure brings Optune tech to drug trial for glioblastoma

July 24, 2017 By Sarah Faulkner

Novocure

Novocure (NSDQ:NVCR) said today that it joined a Phase Ib study to evaluate the safety of Celgene‘s (NSDQ:CELG) marizomib and temozolomide in combination with Optune for patients with newly-diagnosed glioblastoma. The trial is the first to assess Optune, the company’s “Tumor Treating Fields” delivery device, in combination with an investigational drug. Celgene and Triphase changed their ongoing […]

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Neurological, Oncology, Pharmaceuticals, Wall Street Beat Tagged With: Celgene, NovoCure

Leukemia trial to match patients with drugs based on genetic biomarkers

July 19, 2017 By Sarah Faulkner

Leukemia & Lymphoma Society

The Leukemia & Lymphoma Society said today that its expanding its Beat AML Master trial to include five investigational treatments for acute myeloid leukemia. The trial, which launched in October last year, has enrolled 70 patients and has garnered support by Alexion Pharmaceuticals (NSDQ:ALXN), Boehringer Ingelheim, Celgene (NSDQ:CELG) and Gilead Sciences (NSDQ:GILD), all of which are providing investigational […]

Filed Under: Clinical Trials, Featured, Oncology, Pharmaceuticals, Wall Street Beat Tagged With: alexionpharmaceuticals, Boehringer Ingelheim Pharmaceuticals, Celgene, Gilead Sciences

Celgene acquires Delinia, beats on Q4 earnings

January 27, 2017 By Sarah Faulkner

Celgene acquires Delinia, beats on Q4 earnings

Shares in Celgene (NSDQ:CELG) fell yesterday, even though the biopharmaceutical company beat earnings expectations on Wall Street with its 4th quarter results. The Summit, N.J.-based company posted profits of $1.29 million, or $1.61 per share, on sales of $2.9 million for the 3 months ended Dec. 31, for bottom-line growth of 34% on sales growth […]

Filed Under: Featured, MassDevice Earnings Roundup, Mergers & Acquisitions Tagged With: Celgene

Evotec, Celgene ink drug development deal for stem cell treatments for neurodegenerative diseases

December 16, 2016 By Sarah Faulkner

Evotec, Celgene ink drug development deal for stem cell treatements for neurodegenerative diseases

Evotec (ETR:EVT) said today that it inked a 5-year drug discovery and development deal with Celgene (NSDQ:CELG) to identify stem cell therapies for a range of neurodegenerative diseases including amyotrophic lateral sclerosis, Alzheimer’s disease and Parkinson’s disease. According to the agreement, Hamburg, Germany-based Evotec will receive an upfront payment of $45 million and Celgene will hold exclusive […]

Filed Under: Discovery, Distribution, Featured, Neurological, Stem Cells, Wall Street Beat Tagged With: Celgene, Evotec, Harvard University

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Footer

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Design & Outsourcing
Medical Tubing + Extrusion

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery News
Advertise with us
About
Contact us
Privacy
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2021 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS